This Study will evaluate the safety and efficacy of brimonidine in patients with glaucoma or ocular...
Date First Received: September 12, 2005
Last Updated: April 1, 2008
Verified by: Allergan, April 2008
Clinical Trial Phase: Phase 3 | Start Date:
Overall Status: Completed
Estimated Enrollment: 150
Brief Summary
Condition Keyword(s):
Intervention(s):
This Study will evaluate the safety and efficacy of brimonidine in patients with glaucoma or ocular hypertension
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Intervention(s) in this Clinical Trial
- Drug: brimonidine
Outcome Measures for this Clinical Trial
Primary Measures
- lowering of intraocular pressure
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- ocular hypertension or glaucoma in both eyes
- currently treated with brimonidine
- requires IOP-lowering therapy in both eyes
Exclusion Criteria:
- uncontrolled systemic disease
- known allergy or sensitivity to brimonidine
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: Allergan
Additional Information
Information obtained from ClinicalTrials.gov on September 05, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00168363
Study ID Number: 190342-022
ClinicalTrials.gov Identifier: NCT00168363
Health Authority: United States: Food and Drug Administration
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
